Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Department of Cardiology, Inselspital, Bern University Hospital, Bern, Switzerland.
Cardiovasc Diabetol. 2023 Jul 12;22(1):174. doi: 10.1186/s12933-023-01903-7.
Type 2 diabetes (T2D) is expected to worsen the prognosis of inpatients with heart failure (HF) but the evidence from observational studies is inconsistent. We aimed to compare mortality outcomes and life expectancy among inpatients with HF with or without T2D and explored whether chronic kidney disease (CKD) influenced these associations.
We collected hospital and civil registry records of consecutive inpatients from a tertiary hospital in Switzerland with a diagnosis of HF from the year 2015 to 2019. We evaluated the association of T2D with mortality risk using Cox regression and adjusted for confounders.
Our final cohort consisted of 10,532 patients with HF of whom 27% had T2D. The median age (interquartile range [IQR]) was 75 [68 to 82] and 78 [68 to 86] for the diabetes and non-diabetes groups, respectively. Over a median follow-up [IQR] of 4.5 years [3.3 to 5.6], 5,347 (51%) of patients died. T2D patients had higher risk of all-cause mortality (hazard ratio [HR] 1.21, 95% confidence interval [CI] 1.14 to 1.29). Compared to control (i.e. no T2D nor CKD), average life expectancy (95% CI) among T2D patients, CKD, or both was shorter by 5.4 months (95% CI 1.1 to 9.7), 9.0 months (95% CI 8.4 to 9.6), or 14.8 months (95% CI 12.4 to 17.2), respectively. No difference by sex or ejection fraction category was observed.
T2D is associated with a significantly higher risk of all-cause mortality and shorter life expectancy compared to those without among middle-aged and elderly inpatients with HF; presence of CKD may further increase these risks.
2 型糖尿病(T2D)预计会使心力衰竭(HF)住院患者的预后恶化,但观察性研究的证据并不一致。我们旨在比较伴有或不伴有 T2D 的 HF 住院患者的死亡率和预期寿命,并探讨慢性肾脏病(CKD)是否会影响这些关联。
我们从瑞士一家三级医院的 2015 年至 2019 年的连续住院患者的医院和民事登记记录中收集了 HF 诊断数据。我们使用 Cox 回归评估了 T2D 与死亡率风险的关系,并进行了混杂因素调整。
我们的最终队列包括 10532 名 HF 患者,其中 27%患有 T2D。糖尿病组和非糖尿病组的中位年龄(四分位间距[IQR])分别为 75[68 至 82]和 78[68 至 86]。在中位随访[IQR]4.5 年[3.3 至 5.6]期间,5347 名(51%)患者死亡。T2D 患者的全因死亡率风险更高(风险比[HR]1.21,95%置信区间[CI]1.14 至 1.29)。与对照组(即无 T2D 且无 CKD)相比,T2D 患者、CKD 患者或两者兼有时的平均预期寿命(95%CI)分别缩短了 5.4 个月(95%CI 1.1 至 9.7)、9.0 个月(95%CI 8.4 至 9.6)或 14.8 个月(95%CI 12.4 至 17.2)。未观察到性别或射血分数类别差异。
与无 T2D 且无 CKD 的 HF 住院患者相比,中年和老年 HF 住院患者中 T2D 与全因死亡率风险显著增加和预期寿命缩短相关;CKD 的存在可能进一步增加这些风险。